Insulet and Dexcom Partner to Offer Choices for Animas Users
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006532/en/
Welcome Program includes a no cost trial of the Omnipod System, a
free box of Pods (10 count), and the opportunity to receive a
"We created this program to provide a way for Animas users to experience
the freedom of the Omnipod System with the peace of mind of Dexcom's
market-leading CGM," said
"Dexcom is excited to partner with
As the number one pediatric preferred pump3, which is also
quickly gaining adoption with adults, the Omnipod System uses a
tubeless, waterproof patch-pump technology that offers users significant
quality of life benefits. The differentiated design provides up to 72
hours of nonstop, discreet insulin delivery, and more choice for site
selection. It eliminates the burden associated with multiple daily
injections and the complexity associated with traditional tubed pumps.
When used with the Dexcom G5 Mobile CGM, users will benefit from fewer
finger sticks, fewer components to carry and wear, and access to pump
and blood glucose data from their smart-phone with
For full offer details and to get started, Animas patients should call the Insulet Customer Care Team at 1-888-643-8763. Offer terms and conditions are subject to change. Please click here for full promotion details.
1The Omnipod Insulin Management System and the Dexcom G5 CGM are not integrated, are sold separately, and function independently.
2These promotions are two independent offerings and therefore an individual may take advantage of either one separately or both. You may be required to submit a form directly to Dexcom.
3dQ&A Q3 2016
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 28, 2017 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
© 2017 Insulet Corporation and Omnipod are trademarks or registered trademarks of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation.
Investor Relations and Media Contact:
Vice President, Investor Relations and Corporate Communications
News Provided by Acquire Media